Evidence map›Paper›PMID 40552410›Full record

ArticleClinical pharmacology in drug development2025

Disposition and Absolute Bioavailability of Oral Imlunestrant in Healthy Women: A Phase 1, Open-Label Study.

Amita Datta-Mannan, Boris Czeskis, Elaine Shanks, Eunice Yuen, Stephen Hall, Vivian Rodriguez Cruz, Kenneth Cassidy

Abstract readClinical Trial, Phase I
In one paragraph

Article in Clinical pharmacology in drug development, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Amita Datta-MannanEli Lilly and Company, Indianapolis, IN, USA.
Boris CzeskisEli Lilly and Company, Indianapolis, IN, USA.
Elaine ShanksEli Lilly and Company, Bracknell, Berkshire, UK.
Eunice YuenEli Lilly and Company, Bracknell, Berkshire, UK.
Stephen HallEli Lilly and Company, Indianapolis, IN, USA.
Vivian Rodriguez CruzEli Lilly and Company, Indianapolis, IN, USA.
Kenneth CassidyEli Lilly and Company, Indianapolis, IN, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Imlunestrant (LY3484356) is a next-generation orally bioavailable selective estrogen receptor degrader being investigated for the treatment of estrogen receptor-positive advanced breast and endometrial cancers. This Phase 1, open-label, 2-part study evaluated the disposition and absolute bioavailability of [

Indexed as

Administration, OralAdultAgedBiological AvailabilityFecesFemaleHealthy VolunteersHumansMiddle Agedabsolute bioavailabilitybreast cancerdispositionimlunestrantmicrotracerpharmacokineticsselective estrogen receptor degraders

Identifiers

PMID40552410
PMCPMC12486192

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.